• Galectin Therapeutics released a KOL event presentation outlining belapectin, a galectin-3 inhibitor, in MASH cirrhosis with portal hypertension.
• NAVIGATE trial primary composite endpoint in ITT population missed statistical significance for belapectin 2 mg/kg (p=0.278) or 4 mg/kg (p=0.522) versus placebo.
• Per-protocol analysis showed lower varices incidence with belapectin 2 mg/kg versus placebo (p=0.04).
• Safety summary showed similar discontinuation rates across cohorts, including 5.9% placebo, 4.2% belapectin 2 mg/kg, 6.7% belapectin 4 mg/kg.
• Presentation also cited a third-party assessment projecting peak belapectin US sales of 1.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.